Evidence map›Paper›PMID 40586518›Full record

ArticleeLife2025

Expanding automated multiconformer ligand modeling to macrocycles and fragments.

Jessica Flowers, Nathaniel Echols, Galen J Correy, Priyadarshini Jaishankar, Takaya Togo, Adam R Renslo, Henry van den Bedem, James S Fraser, Stephanie A Wankowicz

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jessica FlowersDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-3501-8804
Nathaniel EcholsDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0007-1597-9302
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0001-5155-7325
Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Takaya TogoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0003-0243-0760
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-1240-2846
Henry van den BedemDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0003-2358-841X
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-5080-2859
Stephanie A WankowiczDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-4225-7459

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Danielle L Swaney · 2022 to 2026
$103.4M
Equipment for Discovering and Manipulating Macromolecular Conformational EnsemblesR35GM145238 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$3.1M
National Institute of Allergy and Infectious Diseases U19AI171110NIAID NIH HHS U19 AI171110NIGMS NIH HHS NIHGM145238NIGMS NIH HHS R35 GM145238
6 · The paper itself

Abstract

Small molecule ligands exhibit a diverse range of conformations in solution. Upon binding to a target protein, this conformational diversity is reduced. However, ligands can retain some degree of conformational flexibility even when bound to a receptor. In the Protein Data Bank, a small number of ligands have been modeled with distinct alternative conformations that are supported by macromolecular X-ray crystallography density maps. However, the vast majority of structural models are fit to a single-ligand conformation, potentially ignoring the underlying conformational heterogeneity present in the sample. We previously developed qFit-ligand to sample diverse ligand conformations and to select a parsimonious ensemble consistent with the density. While this approach indicated that many ligands populate alternative conformations, limitations in our sampling procedures often resulted in non-physical conformations and could not model complex ligands like macrocycles. Here, we introduce several improvements to qFit-ligand, including integrating RDKit for stochastic conformational sampling. This new sampling method greatly enriches low-energy conformations of small molecules and macrocycles. We further extended qFit-ligand to identify alternative conformations in PanDDA-modified density maps from high-throughput X-ray fragment screening experiments, as well as single-particle cryo-electron microscopy density maps. The new version of qFit-ligand improves fit to electron density and reduces torsional strain relative to deposited single-conformer models and our prior version of qFit-ligand. These advances enhance the analysis of residual conformational heterogeneity present in ligand-bound structures, which can provide important insights for the rational design of therapeutic agents.

Indexed as

Macrocyclic CompoundsModels, MolecularCrystallography, X-RayDatabases, ProteinLigandsMolecular ConformationLigandsMacrocyclic Compoundscompositional heterogeneityconformational heterogeneitycryo-EMmolecular biophysicsnonesmall moleculesstructural biologyX-ray crystallography

Identifiers

PMID40586518
PMCPMC12208665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.